{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ezetimibe+Tablets&page=2", "query": { "intervention": "Ezetimibe Tablets", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ezetimibe+Tablets&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T17:39:20.321Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00639158", "title": "Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dyslipidemias", "Coronary Heart Disease", "Combined (Atherogenic) Dyslipidemia", "Mixed Dyslipidemia" ], "interventions": [ { "name": "ABT-335", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "atorvastatin", "type": "DRUG" }, { "name": "ezetimibe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 543, "start_date": "2008-02", "completion_date": null, "has_results": true, "last_update_posted_date": "2011-06-13", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 118, "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Columbiana", "state": "Alabama" }, { "city": "Hueytown", "state": "Alabama" }, { "city": "Ozark", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00639158" }, { "nct_id": "NCT04369664", "title": "CHOlesterol Lowering and Residual Risk in Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Statin", "type": "DRUG" }, { "name": "PCSK9 inhibitor", "type": "DRUG" }, { "name": "Ezetimibe 10mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 151, "start_date": "2020-08-12", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04369664" }, { "nct_id": "NCT06021951", "title": "Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Healthy Lactating Women" ], "interventions": [ { "name": "Bempedoic Acid 180 MG Oral Tablet", "type": "DRUG" }, { "name": "Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 16, "start_date": "2023-08-04", "completion_date": "2024-03-22", "has_results": true, "last_update_posted_date": "2025-04-11", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06021951" }, { "nct_id": "NCT03001076", "title": "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia", "Atherosclerosis", "Statin Adverse Reaction" ], "interventions": [ { "name": "Bempedoic acid", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 269, "start_date": "2016-11-29", "completion_date": "2018-02-12", "has_results": true, "last_update_posted_date": "2020-05-11", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 1, "location_summary": "Georgetown, Texas", "locations": [ { "city": "Georgetown", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03001076" }, { "nct_id": "NCT02890992", "title": "An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "alirocumab SAR236553 (REGN727)", "type": "DRUG" }, { "name": "statins", "type": "DRUG" }, { "name": "ezetimibe", "type": "DRUG" }, { "name": "cholestyramine", "type": "DRUG" }, { "name": "fenofibrate", "type": "DRUG" }, { "name": "omega-3 fatty acids", "type": "DRUG" }, { "name": "nicotinic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 42, "start_date": "2016-09-15", "completion_date": "2019-02-22", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 3, "location_summary": "St Louis, Missouri • Charlotte, North Carolina • Cincinnati, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890992" }, { "nct_id": "NCT00762229", "title": "Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Ezetimibe 10 mg", "type": "DRUG" }, { "name": "Ezetimibe 5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bronx VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-07", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2013-06-14", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00762229" }, { "nct_id": "NCT00762164", "title": "Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Vytorin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bronx VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2007-03", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00762164" }, { "nct_id": "NCT01730053", "title": "Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2012-11-30", "completion_date": "2014-05-31", "has_results": true, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 54, "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730053" }, { "nct_id": "NCT01644474", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for Alirocumab)", "type": "DRUG" }, { "name": "Placebo (for Ezetimibe)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2012-07", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 3, "location_summary": "Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644474" }, { "nct_id": "NCT05266586", "title": "Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyslipidemias", "High Cholesterol", "Hypercholesterolemia" ], "interventions": [ { "name": "Obicetrapib", "type": "DRUG" }, { "name": "Ezetimibe 10mg", "type": "DRUG" }, { "name": "Obicetrapib placebo", "type": "OTHER" }, { "name": "Ezetimibe placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "NewAmsterdam Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 119, "start_date": "2022-03-09", "completion_date": "2022-09-08", "has_results": true, "last_update_posted_date": "2024-07-03", "last_synced_at": "2026-09-22T17:39:20.321Z", "location_count": 16, "location_summary": "Los Angeles, California • Northridge, California • Ocala, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05266586" } ] }